GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCR2 Therapeutics Inc (NAS:TCRR) » Definitions » Pretax Margin %

TCR2 Therapeutics (TCR2 Therapeutics) Pretax Margin % : % (As of Mar. 2023)


View and export this data going back to 2019. Start your Free Trial

What is TCR2 Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. TCR2 Therapeutics's Pre-Tax Income for the three months ended in Mar. 2023 was $-40.40 Mil. TCR2 Therapeutics's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Therefore, TCR2 Therapeutics's pretax margin for the quarter that ended in Mar. 2023 was %.

The historical rank and industry rank for TCR2 Therapeutics's Pretax Margin % or its related term are showing as below:


TCRR's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -174.24
* Ranked among companies with meaningful Pretax Margin % only.

TCR2 Therapeutics Pretax Margin % Historical Data

The historical data trend for TCR2 Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TCR2 Therapeutics Pretax Margin % Chart

TCR2 Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Pretax Margin %
Get a 7-Day Free Trial - - - - -

TCR2 Therapeutics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TCR2 Therapeutics's Pretax Margin %

For the Biotechnology subindustry, TCR2 Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TCR2 Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TCR2 Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where TCR2 Therapeutics's Pretax Margin % falls into.



TCR2 Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

TCR2 Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-151.561/0
= %

TCR2 Therapeutics's Pretax Margin for the quarter that ended in Mar. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2023 )/Revenue (Q: Mar. 2023 )
=-40.396/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TCR2 Therapeutics  (NAS:TCRR) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


TCR2 Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of TCR2 Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


TCR2 Therapeutics (TCR2 Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
100 Binney Street, Suite 710, Cambridge, MA, USA, 02142
TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which are effective in patients with solid tumors.
Executives
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Ansbert Gadicke director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Mpm Asset Management Llc 10 percent owner 399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Shawn Tomasello director C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Priti Hegde director TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Rosemary Harrison officer: Chief Business & Strategy C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Garry E Menzel director, officer: President & CEO C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Peter Olagunju officer: Chief Technical Officer TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Alfonso Quintas Cardama officer: Chief Medical Officer C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Angela Justice officer: Chief People Officer 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Eric Sullivan officer: Chief Financial Officer GOODWIN PROCTER LLP, 53 STATE ST, BOSTON MA 02109
Mayur Ian Somaiya officer: Chief Financial Officer TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Axel Hoos director C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142